$1.21
0.05[4.31%]
At close: Apr 26
$1.21
0[0.00%]
After Hours: 8:50AM EDT
Aptose Biosciences
(NASDAQ:APTO)Latest News for Aptose Biosciences Stock (NASDAQ:APTO)
Aptose Biosciences Stock (NASDAQ: APTO)
Categories: All
Wednesday, April 03, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
- Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) EstimateBenzinga Newsdesk - Mar 26, 2024, 4:12PM
- Recap: Aptose Biosciences Q4 EarningsBenzinga Insights - Mar 26, 2024, 4:10PM
- Aptose Reports FY23 Loss Per Share Of $(7.58) vs $(6.80) Loss Last YearBenzinga Newsdesk - Mar 26, 2024, 4:06PM
- Earnings Scheduled For March 26, 2024Benzinga Insights - Mar 26, 2024, 4:47AM
Monday, March 25, 2024
Thursday, February 01, 2024
Friday, January 26, 2024
- Aptose Announces Pricing Of Underwritten Offering Of 4,912,280 Shares At $1.71 Per Share And Concurrent $4 Million Private Placement with Hanmi PharmaceuticalBenzinga Newsdesk - Jan 26, 2024, 8:04AM
- Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 26, 2024, 7:58AM
Monday, December 04, 2023
Friday, November 10, 2023
Thursday, November 09, 2023
Thursday, November 02, 2023
Monday, October 30, 2023
Monday, October 16, 2023
- Aptose Biosciences shares are trading higher after the company announced that two abstracts on tuspetinib, Aptose's Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia.Benzinga Newsdesk - Oct 16, 2023, 12:24PM
- Aptose Biosciences Announced That Two Abstracts On Tuspetinib, Phase 1/2 Myeloid Kinase Inhibitor For Acute Myeloid Leukemia, Have Been Accepted For Poster Presentations At The European School Of Haematology International ConferenceBenzinga Newsdesk - Oct 16, 2023, 7:47AM
Tuesday, October 03, 2023
Thursday, September 07, 2023
Friday, August 11, 2023
- Piper Sandler Maintains Overweight on Aptose Biosciences, Lowers Price Target to $12Benzinga Newsdesk - Aug 11, 2023, 1:52PM
- RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To KnowBenzinga Insights - Aug 11, 2023, 1:00PM
- RBC Capital Maintains Outperform on Aptose Biosciences, Lowers Price Target to $23Benzinga Newsdesk - Aug 11, 2023, 12:00PM
- HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $23Benzinga Newsdesk - Aug 11, 2023, 8:10AM
- Oppenheimer Maintains Outperform on Aptose Biosciences, Lowers Price Target to $15Benzinga Newsdesk - Aug 11, 2023, 7:14AM
Thursday, August 10, 2023
Wednesday, July 26, 2023
Monday, June 26, 2023
Tuesday, June 20, 2023
Monday, June 12, 2023
- Aptose Biosciences shares are trading higher after multiple firms raised their respective price targets.Benzinga Newsdesk - Jun 12, 2023, 12:39PM
- Cantor Fitzgerald Maintains Overweight on Aptose Biosciences, Raises Price Target to $38Benzinga Newsdesk - Jun 12, 2023, 10:33AM
- HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $23Benzinga Newsdesk - Jun 12, 2023, 9:46AM
- Oppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50Benzinga Newsdesk - Jun 12, 2023, 9:44AM
Wednesday, June 07, 2023
Wednesday, May 24, 2023
Tuesday, May 23, 2023
Tuesday, May 09, 2023
- Analyst Expectations for Aptose Biosciences's FutureBenzinga Insights - May 9, 2023, 12:00PM
- Oppenheimer Reiterates Outperform on Aptose Biosciences, Maintains $9 Price TargetBenzinga Newsdesk - May 9, 2023, 10:32AM
- RBC Capital Reiterates Outperform on Aptose Biosciences, Maintains $5 Price TargetBenzinga Newsdesk - May 9, 2023, 10:09AM
- HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $12 Price TargetBenzinga Newsdesk - May 9, 2023, 6:30AM